Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions necessary for maintenance of acid-base balance, isotonicity, and electrodynamic characteristics of cells. Potassium is the principal intracellular cation and is essential for nerve impulse transmission, muscle contraction, and enzymatic function. Dextrose provides calories and may reduce protein and nitrogen loss. Sodium chloride maintains osmotic pressure and fluid balance.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
FDA-approved: Maintenance of electrolyte and fluid balance in patients requiring parenteral nutrition or fluid replacement.,Off-label: Treatment of hypokalemia when oral replacement is not feasible.
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion, 1000 m L to 2000 m L per day at a rate of 100-200 m L/hour, providing 37 m Eq potassium per liter, adjusted based on serum potassium and fluid/electrolyte needs.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Potassium's terminal half-life is approximately 12-24 hours in patients with normal renal function, reflecting redistribution and slow elimination; prolonged in renal impairment. Dextrose half-life is minutes due to rapid metabolism. Sodium half-life is 2-3 days.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Potassium chloride is not metabolized; excreted renally. Dextrose undergoes metabolism via glycolysis. Sodium chloride is not metabolized.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Potassium is primarily excreted renally (approximately 90%) via glomerular filtration and tubular secretion, with about 10% eliminated in feces and minimal biliary excretion. Dextrose and sodium are fully metabolized or excreted renally.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Potassium: 0% bound. Dextrose: 0% bound. Sodium: 0% bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Potassium Vd: approximately 0.5 L/kg (reflects distribution into intracellular and extracellular fluid). Dextrose Vd: ~0.2 L/kg (extracellular and total body water). Sodium Vd: 0.3-0.5 L/kg (extracellular fluid volume).
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% for all components.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR <30 m L/min: Avoid use due to risk of hyperkalemia; consider alternative potassium replacement. GFR 30-50 m L/min: Use with caution, monitor serum potassium closely; maximum infusion rate 10 m Eq/hour. GFR >50 m L/min: No adjustment necessary.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh A: No adjustment needed. Child-Pugh B: Monitor serum potassium; consider reduced rate if ascites present. Child-Pugh C: Avoid use unless potassium deficit severe; monitor closely.
No dosage adjustment required for hepatic impairment.
Weight-based dosing: 0.5-1 m Eq/kg potassium per day, administered as continuous infusion in compatible IV fluid; maximum rate 0.5 m Eq/kg/hour. For solution concentration, each liter provides 37 m Eq potassium; adjust volume accordingly.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Start at lower end of dosing range (e.g., 1000 m L/day) with infusion rate not exceeding 100 m L/hour; monitor renal function and serum potassium frequently due to age-related decline in GFR and increased risk of hyperkalemia.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
No black box warning for this combination product. Potassium chloride concentrate for injection (not this product) has a boxed warning regarding fatal hyperkalemia if administered undiluted.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of hyperkalemia, which can be fatal; monitor serum potassium levels.,Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia.,Solution may contain aluminum; use with caution in renal impairment.,Do not administer simultaneously with blood products through same IV line.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperkalemia,Severe renal impairment with oliguria or anuria,Acute dehydration or heat cramps,Hypersensitivity to any component,Addison's disease,Concomitant use with potassium-sparing diuretics
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, avocados, potatoes) and salt substitutes containing potassium chloride may increase risk of hyperkalemia. Avoid concurrent use of potassium-sparing diuretics (e.g., spironolactone) and ACE inhibitors/ARBs without monitoring.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Potassium chloride is not teratogenic. Dextrose and sodium chloride are physiological components; high doses of dextrose may cause fetal hyperinsulinemia and hypoglycemia at delivery. First trimester: no known teratogenic risk. Second trimester: no known fetal harm. Third trimester: maternal hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Potassium, chloride, dextrose, and sodium are normal milk constituents. Exogenous potassium, dextrose, and sodium chloride are unlikely to produce adverse effects in breastfed infants. No M/P ratio available; considered compatible with breastfeeding.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy induces hypervolemia and increased glomerular filtration rate, potentially altering electrolyte balance. No specific dose adjustment required for potassium chloride, dextrose, or sodium chloride; monitor potassium levels closely, especially in preeclampsia or renal impairment. Dextrose dose may need adjustment to avoid maternal hyperglycemia.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Contains 5 m Eq potassium per liter. Use with caution in renal impairment; monitor serum potassium. Not for rapid potassium repletion; rate limited by dextrose content. Compatible with most IV medications but check for precipitation. Do not administer via central line unless isotonic.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This fluid contains potassium, which helps your heart and muscles work properly.,Tell your doctor if you have kidney problems or are taking potassium supplements or salt substitutes.,Report any chest pain, muscle weakness, or irregular heartbeat during infusion.,Do not consume potassium-rich foods in excess while receiving this IV.,Keep all appointments for blood tests to check your potassium levels.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions necessary for maintenance of acid-base balance, isotonicity, and electrodynamic characteristics of cells. Potassium is the principal intracellular cation and is essential for nerve impulse transmission, muscle contraction, and enzymatic function. Dextrose provides calories and may reduce protein and nitrogen loss. Sodium chloride maintains osmotic pressure and fluid balance.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion, 1000 m L to 2000 m L per day at a rate of 100-200 m L/hour, providing 37 m Eq potassium per liter, adjusted based on serum potassium and fluid/electrolyte needs.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride is not teratogenic. Dextrose and sodium chloride are physiological components; high doses of dextrose may cause fetal hyperinsulinemia and hypoglycemia at delive. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.